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PERKEMBANGAN DAN PENGESAHAN KAEDAH KCPT BAGI PENENTUAN 
HALOPERIDOL DAN HALOPERIDOL TERTURUN SECARA SERENTAK Dl DALAM 
PLASMA : APLIKASI DALAM KAJIAN FARMAKOKINETIK 
Abstrak 
Haloperidol merupakan suatu drug antipsikotik yang tipikal dan secara 
kimianya daripada kumpulan butirofenon. Suatu kaedah kromatografi cecair 
berprestasi tinggi yang peka dan selektif dengan pengesan ultra-lembayung telah 
diperkembangkan bagi penentuan haloperidol dan haloperidol terturun secara serentak 
di dalam plasma. Drug dikesan pada 230 nm. Pemisahan kromatografi dilakukan 
dengan menggunakan turus KCPT lnertsil C8-3 (150 x 4.6 mm, 5f.lm). Fasa bergerak 
yang digunakan terdiri daripada 50 mM larutan penimbal fosfat (pH 5.0) - metanol 
(51 :49, v/v) dengan kadar aliran fasa bergerak 1.0 ml/min. Pengekstrakan cecair-
cecair yang mudah telah dihasilkan dan pirimetamina digunakan sebagai piawai 
dalaman. Purata peratus pengembalian bagi haloperidol, haloperidol terturun dan 
pirimetamina adalah 82.4, 82.1 dan 82.0% masing-masing. Kaedah ini menunjukkan 
selektiviti yang baik di mana tidak terdapat gangguan daripada puncak-puncak drug 
antipsikotik yang lazim digunakan. Keluk kalibrasi adalah linear bagi julat kepekatan 1-
60 ng/ml dengan pekali korelasi ( r ) > 0.999. Peratus pekali variasi bagi kepersisian 
kaedah dalam sehari dan hari ke hari adalah kurang daripada 5%. Had pengesanan 
dan had kuantifikasi bawah adalah 0.5 ng/ml dan 1.0 ng/ml masing-masing bagi 
haloperidol dan haloperidol terturun. 
Stok piawai yang dilarutkan dalam metanol didapati stabil selama tiga 
bulan pada suhu -20°C. Manakala sampel-sampel plasma didapati stabil selama 6 
xvii 
bulan pada suhu-20oc and -85oc Kaedah ini telah diaplikasi dengan jayanya dalam 
kajian farmakokinetik haloperidol di dalam tikus di mana haloperidol diberikan secara 
dos oral (2.5 mg/kg). Nilai purata t112, Cmax. tmax. AUC(o-oo)• CL dan Vd adalah 6.2 ± 2.6 
h, 24.9 ± 7.2 ng/ml, 2.0 ± 1.9 j, 214.1 ± 76.0 ng.j/ml, 213.0 ± 61.9 ml/min/kg dan 110.3 
± 46.3 1/kg masing-masing. Kaedah analisis bagi haloperidol dan haloperidol terturun 
yang telah dihasilkan didapati sesuai bagi kajian farmakokinetik. 
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DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR SIMULTANEOUS 
DETERMINATION OF HALOPERIDOL AND REDUCED HALOPERIDOL IN 
PLASMA: APPLICATION IN PHARMACOKINETIC STUDY 
Abstract 
Haloperidol is a typical antipsychotic drug that chemically belongs to 
butyrophenone group. A sensitive and selective reversed-phase HPLC method with 
ultraviolet detection was developed for the simultaneous determination of haloperidol 
and reduced haloperidol in plasma. Drugs were detected at 230 nm. The 
chromatographic separation was performed on an lnertsil C8-3 (150 x 4.6mm, 5 llm) 
HPLC column. Mobile phase composed. of 50 mM phosphate buffer pH 5.0 and 
methanol (51 :49, v/v) and eluted at 1.0 mllmin. A simple liquid-liquid extraction was 
carried-out using pyrimethamine as an internal standard. The mean extraction recovery 
for haloperidol, reduced haloperidol and pyrimethamine were 82.4, 82.1 and 82.0% 
respectively. The method showed good selectivity with respect to commonly 
administered psychotropic drugs. Calibration curve was linear over the concentration 
range 1 - 60 ng/ml with the correlation coefficient (r) > 0.999. The within-day and day-to 
-day assay precision was less than 5%. Limit of detection and lower limit of 
quantification were 0.5 ng/ml and 1 ng/ml respectively for haloperidol and reduced 
haloperidol. 
Stock standard of haloperidol and reduced haloperidol in methanol were 
stable up to three months at -20°C. Plasma samples spiked with haloperidol and 
reduced haloperidol was stable up to 6 months at -20°C and -85°C. The method was 
successfully applied to pharmacokinetic study of haloperidol in rats following oral dose 
of haloperidol (2.5 mg/kg). The mean t112. Cmax. tmax. AUC (O-oo)• CL and Vd were 6.2 ± 2.6 
xix 
h, 24.9 ± 7.2 ng/ml, 2.0 ± 1.9 h, 214.1 ± 76.0 ng.h/ml, 213.0 ± 61.9 ml/min/kg and 
110.3 ± 46.3 1/kg respectively. The analytical method for haloperidol and reduced 
haloperidol assay is found to be suitable for pharmacokinetic studies. 
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1.1 PSYCHOSIS 
CHAPTER 1 
INTRODUCTION 
Psychosis is a mental disorder which involves striking disturbances of 
thought, perception, affect, and behaviour (Pantelis et a/., 2003). The expression of 
psychotic symptoms varies over time and across patients, however the cumulative 
effects of the illness are always severe and usually long lasting (Sadock & Sadock, 
2000). There are various types of psychotic disorders such as anxiety, bipolar disorder 
(manic disorder), depression and schizophrenia (Grilly, 1994). These disorder a briefly 
discussed in the following sections. 
1.1.1 ANXIETY 
Anxiety is a normal response to psychological stress induced by either 
physical or perceived threat. However, a malfunctioning anxiety response could lead to 
anxiety disorders. Anxiety disorders are further divided into five types; such as panic 
disorder, social phobia, obsessive compulsive disorder, generalised anxiety disorder 
and posttraumatic stress disorder (Leveleki et a/., 2006; Ballenger, 1999). Patients 
suffering from anxiety disorder are usually treated either by medication or 
psychotherapy (Ballenger, 1999). 
1.1.2 MANIA OR BIPOLAR DISORDER 
Mania or bipolar disorder is a brain disorder that causes unusual shifts 
in a person's mood, energy and ability to function. During a manic episode, the mood 
disturbances are severe enough to cause significant impairment in occupational 
functioning or in otherwise normal social activities (Schapiro, 2005). Bipolar disorder is 
further classified into two groups namely Bipolar I and Bipolar II. Bipolar I is 
characterised by one or more manic or mixed episodes. Bipolar II is characterised by 
1 
recurrent episodes of major depression and hypomania. Bipolar disorder affects 
approximately three to five percent of the world's population, and affects both sexes 
equally in all age group (Shastry, 2005). 
1.1.3 DEPRESSION 
Depression is defined as a feeling of intense sadness. Depressed 
individuals tend to be obsessed with personal failings, are apathetic and socially 
withdrawn (Malatynska & Knapp, 2005). Depression disorder can be transmitted in the 
form of negative emotions from living or non-living beings to susceptible host. 
Therefore, depression is also known as communicable disorder (Kalra, 2004). 
Symptoms of depression disorder can last periods of time, sometimes several to years 
(Gard, 2001 ). 
1.1.4 SCHIZOPHRENIA 
Schizophrenia is a complex cognitive disorder comprising of a variety of 
alterations in attention, working memory, language, response monitoring and inhibition 
(Freedman, 2003). Schizophrenia is treated as a debilitating disorder of the central 
nervous system. Its symptoms are divided into two classes namely positive symptoms 
and negative symptoms. Positive symptoms include hallucinations, delusions, 
conceptual disorganization, where negative symptoms include social withdrawal, 
blunted affect, and poverty of speech (Sawa & Snyder, 2002; Donaldson eta/., 1983). 
This disorder reduces the ability of the individual to interact with the social. 
Schizophrenia affects about 1% of the world's population (Buchanan & Carpenter, 
2000). All these types of mental disorders mentioned above are treated with 
antipsychotic drug that will be described in the following section. 
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1.2 ANTIPSYCHOTIC DRUG 
The term antipsychotic is applied to a group of drugs used to treat 
psychosis. These classes of drugs were originally called 'neuroleptics' (from the Latin 
root which mean to grasp the neuron) (Nicholas, 2004). Antipsychotic drugs are 
generally divided in two types; that is typical antipsychotic drug and atypical 
antipsychotic drug. 
1.2.1 TYPICAL ANTIPSYCHOTIC DRUG 
Typical antipsychotics are also known as major tranquilizers because of 
their tranquilising and sedating effects when taken in large doses. Typical antipsychotic 
drugs are effective primarily against positive symptoms of schizophrenia. Such drugs 
include haloperidol (HP), chlorpromazine, perphenazine, thioridazine and 
. 
trifluoperazine are examples of typical antipsychotic drug (Fig. 1.1 ). Chlorpromazine 
was the first typical antipsychotic drug used in 1952 to treat schizophrenic patients 
(Edliner et a/., 2005). Antipsychotic properties of typical antipsychotics are achieved 
through the antagonistic effect on dopamine receptors. 
The typical antipsychotic drugs used to treat schizophrenia are highly 
effective. In particular, HP, the most widely used typical antipsychotic is very efficient in 
treating the positive symptoms of schizophrenia. The most predominant among these 
symptoms are dystonia, parkinsonian-like syndrome, and tardive dyskinesia 
(Andreassen eta/., 1996). 
1.2.2 A TYPICAL ANTIPSYCHOTIC DRUG 
Atypical antipsychotic drugs are used to treat schizophrenic patients 
and results less extrapyramidal side effects. Compared to the older 'typical' 
antipsychotic, the atypical antipsychotic drugs are equally effective against the positive 
symptoms and the negative symptoms of schizophrenia. Atypical antipsychotic drugs 
3 
block both dopamine and serotonin (5-hyroxytryptamine) receptors. These combined 
effects on both dopamine and serotonin (5-hyroxytryptamine) receptors explain the 
lower extrapyramidal side effects of atypical antipsychotic drugs. Examples of atypical 
antipsychotic drugs are ariprazole, risperidone, clozapine, olanzapine, quetiapine and 
ziprasidone (Fig. 1.2). 
1.3 HALOPERIDOL 
HP is {4-[4-(p-chlorophenyl)-4-hydroxypiperidino] 4'-flurobutyrophenone} 
a typical butyrophenone antipsychotic drug. HP is a tertiary amine that occurs as a 
white or almost white powder, is practically insoluble in water, and is slightly soluble in 
alcohol, methanol (MeOH) and methylene chloride. The melting point of HP is 150 to 
153°C. The empirical formula for HP is C21 H23CIFN03 (8 P, 2003). The drug has a 
pKa value of 8.3 (AHFS, 2000). 
HP is effective in the treatment of many psychotic disorders such as 
hyperactivity, agitation and mania (Robert & Allain, 2001). HP effectively treats positive 
symptoms of schizophrenia (Glick et a/., 2001) while ineffective against negative 
symptoms of schizophrenia. HP is also used in the treatment of neurological disorders 
such as Gilles de Ia Tourette syndrome, Huntington's chorea and acute/chronic brain 
syndrome (Silver et a/., 2001; Barr et a!., 1988; Maltbie & Cavenar, 1977). Long-term 
use of HP can result in side effects resembling Parkinson's disease and tardive 
dyskinesia, an irreversible motor disorder (Fuxe eta/., 1989). 
Nearly 40 years after its discovery, HP is still one of the most popular 
drug used for the management of various classes of psychosis. The pharmacology of 
HP has been extensively reported (Janssen, 1967). Different assay methods have 
been described in the literature, which will be discussed in the following section. 
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Figure 1.1 Structural formula of typical antipsychotic drugs. 
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a. Clozapine b. Olanzapine 
c. Quetiapine d. Risperidone 
Figure 1.2 Structural formula of atypical antipsychotic drugs. 
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1.3.1 ASSAY OF HPAND RH IN BIOLOGICAL FLUIDS 
Several analytical methods have been reported in the literature for the 
determination of either HP or RH or both drugs in biological fluids. All these methods 
involve various types of detection techniques (Table 1.1 ). Selection of a detection 
technique depends on the types of analytes, and the sensitivity required. For routine 
analysis, the most commonly used detection techniques are ultraviolet (UV) and 
electrochemical (EC) methods. 
A number of techniques are available in the literature for the 
determination of HP in plasma. Some of these include gas chromatography (Bianchetti 
& Morselli, 1978), radioimmunoassay (Clark et a/., 1977) and UV methods (Kogan et 
a/., 1983; Miyazaki & Arita, 1981). Pharmacological studies showed that reduced 
haloperidol (RH), metabolite of HP is pharmacologically active. Therefore, a routine 
method for determination of plasma level should include both HP and RH. 
Simultaneous determinations of HP and RH in human plasma by HPLC system 
coupled with UV (Miller & Devane, 1986; Cahard eta/., 1990; Park eta/., 1991) or EC 
(Aravagiri eta/., 1994; Korpi eta/., 1983; Eddington & Young, 1988) method have been 
reported. 
Although HPLC with EC detection is highly sensitive, it involves the use 
of high voltage that can be problematic in monitoring HP plasma levels (Parkinson, 
1985). Furthermore, increased interference from co-administered drugs is observed in 
assay (Pan eta/., 1998). Several other methods reported in the literature include gas 
chromatography with nitrogen-phosphorus or electron-capture detector (Bianchetti & 
Morselli, 1978; Franklin, 1980; Forsman eta/., 1974) and radioimmunoassay (Clark et 
a/., 1977; Browning et a/, 1985), are relatively time consuming and not a common 
routine method in many therapeutic drug monitoring laboratories. The 
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radioimmunoassay method is very cumbersome and lack specificity and sensitivity and 
with it, RH is determined by an indirect method. 
Recently, liquid chromatography in combination with mass 
spectrometric detection (Hempenius eta/., 1999; Hoja eta/., 1997) has been reported 
for the analysis of HP. Sophisticated detector such as mass spectrometry coupled with 
liquid chromatography or gas chromatography is admittedly highly sensitive. However, 
it is very expensive and requires great expertise in order to operate. With such 
considerations in mind, a method based on UV detection is still the most practical for 
routine applications and therefore is the method of choice in this thesis. 
For analysis of drugs and its metabolites in plasma, sample preparation 
is very important. HP and RH were extracted from biological fluids either by liquid-liquid 
extraction (LLE) or solid phase extraction (SPE) (Table 1.2). However, LLE is the most 
popular and convenient method for routine analysis of HP and RH determinations 
(Korpi eta/., 1983; Miller & Devane, 1986; Hariharan eta/., 1989; Park eta/., 1991). 
Only a few groups used the SPE method (Hempenius eta/., 1999; Hoffman & Edkinds, 
1994; Cahard eta/., 1990). LLE extraction involves single, double or multiple step of 
extraction. Extraction efficiency partly depends on the types of extraction solvents, 
sample preparation pH, back extraction solvents and physiochemical properties. 
Different types of extraction solvents are used to extract drug from plasma. In most 
case mixtures of organic non-polar and polar solvents are employed. For HP and RH 
determinations commonly used non-polar solvents are pentane, hexane and heptane 
and polar solvents are isoamyl alcohol and isopropanol (Table 1.2). However, from the 
reported recovery data presented in Table 1.2 it is difficult to conclude which 
combination of extraction solvents were the best, since extraction performance depend 
on several factors. 
8 
To keep drugs in a neutral state, basifying agents are generally added 
to plasma. Sodium hydroxide (Hariharan eta/., 1989; Miller & Devane, 1986; Jatlow et 
a/., 1982} and sodium carbonate (Aravagiri eta/., 1994; Midha eta/., 1988} at different 
concentrations were used as basifying agents for HP determination in plasma. 
Different types of solvents are used to back extract the drug from 
organic phase into aqueous phase. For HP and RH determination hydrochloric acid 
(Midha et a/., 1988; Miller & Devane, 1986; Hoja et a/., 1997}, perchloric acid 
(Hariharan eta/., 1989} and sulfuric acid (McBurney & George, 1984; Park eta/., 1991} 
were used as back extraction solvents. However, organic acid (perchloric acid and 
acetic acid} are the preferred back extraction solvent as compared to inorganic acid 
(hydrochloric acid and sulphuric acid}. A much cleaner blank chromatogram was 
obtained using perchloric acid rather than hydrochloric acid or sulphuric acid 
(Hariharan eta/., 1989}. 
1.3.2 PHARMACOLOGY OF HP 
A pharmacological action of drug is dependent upon its chemical 
structure, any change in chemical structure may change the drug action. The exact 
drug action also depends on its binding affinity to the receptor types. Drugs combine 
with these receptors to produce their pharmacological effect (Gard, 2001 }. 
Pharmacological activity of HP is related to its affinity for the dopamine 
receptors. (Beuger et a/., 1996; Creese et a/., 1976; Seeman & Lee, 1975; Seeman et 
a/., 1974}. Dopamine receptors are classified into five subtypes such as D1, D2, D3, D4 
and Ds (Dearry eta/., 1990; Grandy eta/., 1991; Monsma eta/., 1990; Sokoloff eta/., 
1990; Sunahara et a/., 1991; Vantol et a/., 1991 }. These receptors are further divided 
into two subfamilies such as the D1-like receptors (D1 and D5) and the Drlike receptors 
(D2, D3 and D4}(Tarazi, 2001}. The binding of HP to the postsynaptic D2-like receptors 
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is believed to mediate the therapeutic effects (Creese et a/., 1976; Seeman & Lee, 
1975; Seeman eta/., 1974). In addition to the specific functions of several subtypes, 
dopamine receptors also have distinct functions based on their location at the neuron, 
i.e. pre-synaptically or post-synaptically (Nagy eta/., 1978). Post-synaptic dopamine 
receptors are necessary for signal initiations or transmission, whereas pre-synaptic 
dopamine receptors, located on the cell bodies and axon terminals, function as 
autoreceptors through which the release of dopamine can be regulated. 
HP, which is a dopamine antagonist, mimics the dopamine in binding to 
the dopamine receptor. There appears to be a very narrow range between the effective 
therapeutic dose for the management of acute psychotic disorder and that, which 
causes extrapyramidal side effects (AHFS, 2000). Therefore, the determination of 
antipsychotic drugs plasma concentration in psychiatric patient is important, especially 
in case of the HP, due to large variability between individuals. When HP is metabolised 
in the liver it produces the metabolite RH. This reduced metabolite, RH is then oxidised 
back to HP. Therefore, the influence of HP and RH on clinical responses requires the 
monitoring of plasma levels for better patient management during HP therapy. 
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Table 1.1 Summary of analytical method for HP determination in biological matrix. 
References Detector Internal standard Column Mobile phase Extraction LOQ/ Recovery 
method LOD (%) 
Miyazaki & HPLC-UV Diphenylamine C18 Nucleosil Methanol-0.2 M LLE 5 ng/ml HP :102% 
Arita. (1981) 250 nm 250 x4 mm, ammonium acetate (LOD) 
i.d. 5!lm (63:37, v/v) 
Jatlow et a/. HPLC-UV Desipramine C18 Bio-sil ODS Acetonitrile-Potassium LLE 1 ng/ml HP :78% 
(1982) 195 nm 250mm dihydrogen phosphate (LOD) 
i.d. 10 1-1m pH3.8-4 (40:60, v/v) 
Kogan eta/. HPLC-UV Chlorohaloperidol C18 Absorbosphere Acetonitrile-0.4 ml LLE 2 ng/ml HP :80% 
(1983) 254nm 100 x 4.6 mm, concentrated sulfuric (LOD) 
i.d. 3!lm acid, 1.1 g tetramethyl 
ammonium chloride, 0.5 
ml triethylamine per liter 
(45:55, v/v) 
Korpi eta/. HPLC-EC Chlorohaloperidol 1-1Bondapak CN Acetonitrile-pot~ssium LLE 0.5 ng/ml HP:92% (1983) 300 x 3.9 mm, phosphate buffer pH (LOD) RH:93% 
i.d. 10 1-1m 6.8 (45:55, v/v) 
Dhar & Kutt. HPLC-UV Chloro-substitute C8 bonded RP Acetonitrile-methanol- LLE 1 j.Jg/1 HP:89% (1984) 254nm analog 250 x4.6 mm, 16.5mm disodium (LOD) 
i.d. 51-1m hidrogen phosphate pHS (45:25:30, v/v/v) 
Miller& HPLC-UV Chlorohaloperidol C18 Acetonitrile-100 mm LLE 2 ng/ml HP:86% Devane. (1986) 196 nm 250 x4.6 mm, monobasic potassium (LOD) RH:92% 
i.d.10!lm phosphate pH 3.8-4 (55:45, v/v) flow rate : 
2.0 ml/min 
---------
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Table 1.1 continued 
References Detector Internal standard Column Mobile phase Extraction LOQ/LOD Recovery 
method (%) 
Eddington & HPLC-EC Chlorohaloperidol Nitrile bonded LC- Acetonitrile-1-propanol- SPE 20 pg HP :93% 
Young. (1988) PCN 1 0 mm dipotassium (LOD) RH :90% 
150 x 4.6 mm, hidrogen phosphate pH 
i.d. 5J.Lm 6.8 (30 :20 :50, v/v/v) 
flow rate : 1.1 ml/min 
Hariharan et HPLC- Bromoperidol CB RP (DB) Acetonitrile-methanol- LLE 50 ng/1 HP :83% 
at. (1989) coulometri 250 x4.6 mm, 50 mM KH2P04 pH 7 (LOD) RH :76% 
i.d. 5J.lm (20:40:40, v/v/v) 
Cahard et a/. HPLC-UV Chlorohaloperidol C18 J.LBondapak Acetonitrile-water -0.025 SPE 1 ng/ml (1990) 220nm 300x3.9 mm, M potassium (LOQ) 
i.d.10 J.lm dihydrogenphosphate (45:5:50, v/v/v) flow 
rate 0.8 ml/min 
Wilhelm& Photo- Clonazepam Silica 100 RP-18 Gradient : ethanol- SPE 450 pg/ml HP :101% 
Kemper. diode 120 x4 mm, acetonitrile-0.05 M (LOQ) (1990) i.d. 5J.Lm phosphate buffer pH2.9 (22:8:70, vlv/v) 
Park eta/. HPLC-UV Bromoperidol C18- Nova Pak Acetonitrile-methanol- LLE 0.5 ng/ml HP :95% (1991) 214 nm 150 x 2.9 mm, 0.5 M potassium (LOD) RH :73% 
i.d.4J.Lm dihydrogen phosphate (31 :11:58, v/v/vl) 
Flow rate : 0.6 mUmin 
Aravagiri et a/. HPLC-EC Chlorohaloperidol Ultrasphere Cyano Acetonitrile-methanol- LLE 0.1 ng/ml HP :68% (1994) 250 x4.6 mm, 0.04M ammonium (LOQ) RH:86% 
i.d. 5 J.lm acetate pH 6.8 (86:6:8, 
v/v/v) 
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Table 1.1 continued 
References Detector Internal standard Column Mobile phase Extraction LOQ/LOD Recovery 
method _(%} 
Hoffman & HPLC- Chlorohaloperidol Microsorb- Methanol-50mM SPE 0.5 ng/ml HP :80% 
Edkins. (1994) coulometri 100 x 4.6 mm, sodium phosphate pH (LOD) 
i.d. 3J..t.m 6.5 (50:50, v/v) 
Flow rate : 0.5ml/min 
Hoja eta/. LC-EC-MS Chlorohaloperidol C18 Nucleosil Acetonitrile-0.04M LLE 0.075 HP :58% 
(!997) 150 x 1 mm, ammonium formate ng/ml RH:70% 
i.d. 5J..t.m (45:55, vlv) (LOD) 
Pan eta/. HPLC-UV Chlorohaloperidol C18 Symmetry Acetonitrile-D. 02M LLE 2 ng/ml HP :99-
(1998) 220nm 150 x 3.9 mm, sodium dihydrogen (LOQ) 104% 
i.d.5 phosphate pH 3.8 
HPLC-EC Altima CN (29:71, v/v) 0.5 ng/ml HP :83-
250 x4.6 mm, Acetonitrile-Methanol- (LOQ) 121% 
i.d. 5J..t.m 0.04M sodium 
dihydrogen phosphate 
pH 6.8 (35:20:45, v/v/v)l 
Hempenius et LC-MS Haloperidol 04 C18 Symmetry Methanol-0.2% formic SPE 0.1 (LLQ) 
a/. (1999) 100 x4.6 mm, acid (50:50, v/v) 
i.d. 3.5 J..l.m 
Titier et a/. HPLC-UV Methylrisperidone C8 Symmetry Gradient : Acetonitrile- LLE 5 ng/ml HP:69% (2003) 240nm i.d. 250 x 4.6 mm, 50mM NaH2P04 (LOQ) 
--------------· --- -
L .. _ 
Abbreviation: HPLC-UV = High performance liquid chromatography-Ultraviolet detector; HPLC-EC= High performance liquid 
chromatography-electrochemical detector; LC-EC-MS= liquid chromatographic-electrospray mass spectrometric; LC-MS= liquid 
chromatographic mass spectrometric; i.d.= internal diamension; mm=milimeter; J..t.m=mikrometer; nm=nanometer; LLE = liquid-liquid 
extraction; SPE= solid phase extraction; LLOQ=Iower limit of quantification, LOQ=Iimit of quantification; LOD=Iimit of detection; 
HP=haloperidol; RH=reduced haloperidol. 
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Table 1.2 Summary of extraction method for HP determination in biological matrix. 
References Extraction solvent Basifying agent Back extraction solvent Reconstitute solvent 
Titier et a/. (2003) Hexane : isoamylalcohol Sodium hydroxide Hydrochloric acid(0.05 Direct injection 
(99: 1, v/v) (7 ml) (2 N, 100 1JI)) M, 200 IJI) 
Pan eta/. (1998) Hexane : isoamylalcohol Sodium hydroxide Hydrochloric acid (0.1 Mobile phase 
(1 00:2, v/v) (5 ml) (2 N, 2001JI) N, 150 IJI) 
Hoja eta/. (1997) Hexane : isoamylalcohol Sodium hydroxide Hydrochloric acid (0.2 Mobile phase 
(99: 1 , v/v) (8 ml) (2M, 5001JI) M, 1ml) (50 IJI) 
Aravagiri et a/. Pentane:methylchloride Saturated sodium Acetonitrile (1501JI) 
(1994) (90: 10, v/v) (7 ml) carbonate (0.5 ml) 
Park eta/. (1991) Hexane : isoamylalcohol Sodium hydroxide Sulphuric acid (0.025 M, Direct injection 
( 98 :2, v/v) (5 ml) (2M, 300-500 j.JI) 120 IJI) 
. 
Hariharan et a/. Pentane : isopropanol Sodium hydroxide Perchloric acid (1 00 Mobile phase 
(1989) (95:5, v/v) (6 ml) (14.8 mol/1, 5 drop) mM, 2ml) (100j.J) 
Midha eta/. (1988) Isopropanol : n pentane Saturated sodium Hydrochloric acid (0.1 Acetonitrile 
( 5 :95, v/v) (10 ml) carbonate (0.5ml) N, 1ml) (401J) 
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Table 1.2 continued 
References Extraction solvent Basifying agent Back extraction solvent Reconstitute solvent 
Miller & Devane. Hexane : isoamylalcohol Sodium hydroxide Hydrochloric acid (0.1 Direct inject 
(1986) (98 :2, v/v) (6 ml) (5M, 1001JI) M, 1001JI) 
McBurney & George. Heptane : isoamylalcohol Sodium hydroxide Sulphuric acid (0.005 M, Methanol 
(1984) (98.5 :1.5, v/v) (2M, 1 ml) 2m I) 
Dhar & Kutt. (1984) Heptane : isoamylalcohol Sodium hydroxide Sulphuric acid (5 mM, Direct injection 
(15% in 1L) (5 ml) (1 mol/1, 0.5 ml) 0.6ml) 
Jatlow eta/. (1983) Hexane : isoamylalcohol Sodium hydroxide Hydrochloric acid (0.1 Direct injection 
( 98 :2, v/v) (1 0 ml) (2M, 0.2 ml) M, 1501JI) 
Miyazaki & Arita. Diethylether (4 ml) Sodium hydroxide Hydrochloric acid (0.1 Direct injection 
(1981) (1 N, 1 ml) N, 3.5ml) • 
Bianchetti & Morselli. Diethyleter (5 ml) Sodium hydroxide Hydrochloric acid (0.2 
(1978) (2 N, 200 1.11 ) N, 2.5ml) 
Hempenius et a/. Solid phase extraction 
(1999) 
Hoffman & Edkinds. Solid phase extraction 
(1994) 
Cahard eta/. (1990) Solid phase extraction 
Abbreviation: 
ml= mililiter; IJI=microliter; M=molarity; N=normality; l=liter; mol/l=mol per liter; v/v=volume by volume; mM=milimolar 
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1.3.3 PHARMACOKINETICS OF HP AND RH 
Numerous articles related to the absorption, distribution, metabolism 
and excretion of HP in animal (Braun et a/., 1967; Soujin et a/., 1967) and human 
(Cressman eta/., 1974) have been reported. In most of these studies, pharmacokinetic 
characteristics of HP are usually reported after a single oral and intramuscular (IM) 
(Cressman eta/., 1974) or intravenous (IV) administration in healthy volunteers (Holley 
et a/., 1983; Chakraborty eta/., 1989) and in schizophrenic patients (Cheng et a/., 
1987). A summary of the HP and RH pharmacokinetic parameters in animal and 
human are shown in Table 1.3. 
HP is a lipophillic compound and therefore is rapidly absorbed from the 
gastrointestinal tract following oral administration, and undergoes a first pass 
metabolism in the liver. Due to the first-pass metabolism in the liver, plasma levels of 
HP occurs within 2 to 6 h after oral dosing (Kunka & Perel, 1989) and about 20 min 
after IM administration (Cressman et a/., 1974) and the systemic bioavailability is 
approximately 75% (Adam & Fernandez 1987; Javaid, 1994). Oral bioavailability is 
about 65% after first pass metabolism {Holley eta/., 1983). 
HP is bound to plasma protein and the free fraction in serum is reported 
to be about 8 %( Forsman & Ohman, 1977a). It is widely distributed in the body and 
crosses the blood brain barrier and is also distributed in breast milk. 
Pharmacokinetic studies of RH in normal volunteers (Chakraborthy et 
a/., 1989; Midha eta/., 1989) and schizophrenic patients (Chang eta/., 1989a) have 
been reported. In a study by Chang eta/ (1989a), a single 10 mg dose of reduced 
haloperidol was given orally to seven male schizophrenic patients (age 43.4± 8.6 
years; weight 54.6 ± 9.0 kg). The pharmacokinetic parameter of RH is shown in Table 
1.3. 
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Table 1.3 
---- - ~ - s --- ------- foh k" fl 
-- -----------------~-- --- --- --· .... 
References Model Route No Dose t1/2 (h) 
(_mg) 
Haloj:>_eridol 
Cheng eta/. Human Intravenous 6 1.5- 5.0 18.8 ± 4.7 
(1987) (67 ± 16kg) Oral 8 2.0-5.0 18.1 ± 4.5 
Holley eta/. Human Intravenous 6 0.125 26.2 ± 8.0 
(1983) (70.9 ± Oral 8 0.503 14.5 ± 3.2 
7.0kg) 
Magliozzi & Human Intravenous 6 0.125 15.1 ± 2.5 
Hollister. Oral 6 0.500 17.5 ± 8.7 
(1985) 
Forsman eta/. Human Intravenous 3 5 12.6 
(1974) 
Cheng & Paalzow. Rats Intravenous 6-8 0.5 1.53 
(1992) (190- 250g) 1.0 1.54 
2.5 1.54 
Wurzburger eta/. Rats Intravenous 0.25 2.69 
(1981) (300- 350g) 0.5 2.60 
1.0 2.50 
Reduced haloperidol 
Chang eta/. Human Oral 7 10 67.0 ± 51.3 
(1989a) (54.6 ± 9.0 
~~ 
Note: 
a = Clearance reported at unit ml min·1 kg·1 ; b = Clearance reported at unit ml/min 
c = Clearance reported at unit 1/h/kg and d = AUC reported at unit IJQ.IIh 
Abbreviations: 
Vd (1/kg) 
9.5 ± 1.9 
21.7±6.9 
NR 
27 
4.3 
5.6 
.6.5 
3.33 
4.60 
4.50 
46.0 ± 20.2 
t112 =elimination half-life; Vd=apparent volume of distribution; CL=clearance; NR=not reported 
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. ',~~~,. 
CL (1/h) AUC (ng.h/ml) 
I 
33 ± 7.8 NR 
I 
' 
49.2 ± 12 NR 
NR NR 
I 
NR NR 
86.28 5724.5 ±4.6 
82.38 11874.2 ± 3.0 
80.78 32110.4 ± 2.9 
53.2° 80.1 
46.7b 174 
42.2b 378 
0.60 ±0.30c 448.5 ± 336.0° 
Table 1.4 Concentration of HP and RH in rat tissues after a single intraperitoneally injection of HP or RH ( 1 mg/kg body weight) ( Korpi & 
Wyatt, 1984). 
Tissue/time after injection HP treatment RH treatment 
HP RH HP RH 
Plasma 
10 min 0.2 ± 0.1 n.d. 0.0 ± 0.0 0.1 ± 0.1 
30min 0.1 ± 0.0 n.d. 0.0 ± 0.0 0.1 ± 0.0 
120 min 0.1 ± 0.0 n.d. 0.0 ± 0.0 0.0 ± 0.0 
Liver 
10 min 24.0 ± 7.8 0.4 ± 0.2 6.8 ± 0.5 1.8 ± 0.1 
30min 6.2 ± 0.2 0.1 ± 0.0 3.1 ± 0.1 0.8 ± 0.1 
120 min 2.9 ± 0.2 0.0 ± 0.0 2.1 ± 0.1 0.3 ± 0.0 
Corpus striatum 
10 min 3.4 ± 1.3 n.d. 0.2 ± 0.0 1.6 ± 1.3 
30min 3.2 ± 0.5 n.d. 0.5 ± 0.1 2.3 ± 0.9 
120 min 1.2 ± 0.2 n.d. 0.6 ± 0.1 0.6 ± 0.2 
Drug concentrations are given as mean ± S.E.M. (n=4) in !Jmol/1 for plasma and in IJmol/kg wet weight for liver and corpus striatum. 
n.d.= not detected. 
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Table 1.5 Concentration of HP and RH in striatum and plasma after repeated IP injections of HP(Chang eta/., 1988). 
Drua concentration Dose 
(mg/kg) Striatum (ng/g} !..P~Ia!.2s!..!..m~a'-l(!.!;ng:l!./!.!m!!JI)~..__ ____________ _ 
HP RH HP RH 
0.1 
0.5 
2 
138 ± 5 
220 ± 11 
436 ± 17 
168 ± 10 
433 ± 16 
2158 ± 155 
All values are mean ± S.E.M. of six to eight animals 
Table 1.6 
References 
Chakraborty 
eta/., 1989 
Jann eta/., 
1990 
Note: 
Pharmacokinetic ~arameters after administration of HP and RH. 
Subject No Drug Dose 
Healthy volunteers 15 HP (given HP 5 mg) 
77.6 ± 10kg RH (given HP 5 mg) 
HP (given RH 5 mg) 
RH (given RH 5 mg) 
Schizophrenic 6 HP (given HP 10 mg) 
43-66 kg RH (given HP 10 mg) 
HP (given RH 1 0 mg) 
RH (given RH 1 0 mg) 
1.8 ± 0.2 
4.4 ± 0.4 
11.1 ± 0.6 
5.0 ± 0.4 
28.8 ± 2.0 
149.6 ± 6.0 
12harmacokinetic 12arameters 
AUC (ng.h/ml) CL (1/kg) 
70.7 ± 33.4 NR 
62.0 ± 103.1 NR 
tl NR 
54.5 ± 20.9 NR 
200.5 ± 99.2b 1.1 ± 0.3c 
85.0 ± 72.2b 6.2 ± 8.8c 
48.2 ± 66.4b 11.5 ± 10.9c 
432.5 ± 336.3b 0.7 ± 0.6c 
t1/2 (h) 
53.9 ± 24.5 
69.2 ± 23.9 
a 
73.2 ± 29.4 
21.5 ± 9.1 
34.0 ± 22.5 
36.7 ± 48.0 
71.9 ± 61.2 
a= could not be calculated in 14 out of 15 volunteers because HP not determined given RH dose. b= AUG reported at unit mcg.h/1. 
CL =Clearance reported as unit 1/h/kg. 
Abbreviation: AUG= Area under the curve; HP =Haloperidol; RH =Reduced haloperidol; kg=kilogram; mg=miligram. 
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The liver is the major site of HP metabolism (Korpi et a/., 1985). The 
metabolism of the HP in humans involves the initial cleavage of the molecule at the C-
N bond of the central chain to form an inactive piperidine and 4-fluorobenzoylpropionic 
acid metabolites (Forsman eta/., 1977) (Figure 1.3) and the formation of a conjugate 
with glucuronic acid at the hydroxy group (Oida et a/., 1989). HP is also metabolised 
through reduction at the benzylic ketone group to form an alcohol metabolite, known as 
reduced haloperidol (RH) (Forsman & Larsson, 1978). 
HP is excreted slowly in the urine and faeces. About 30% of a given 
dose is excreted in urine and about 20% of a given dose in faeces via biliary 
elimination (Beresford & Ward, 1987). Only 1% of a given dose is excreted as 
unchanged drug in the urine (Forsman et a/., 1977). There is also evidence of 
enterohepatic recycling (Chakraborty eta/., 1989). 
The interconversion between HP and RH are species specific. RH is 
oxidised back to HP in rats (Table 1.4) (Korpi & Wyatt 1984; Korpi eta/., 1985a), while 
in guinea pigs reversible metabolism of HP and RH (reduction and oxidation of both 
compounds) were found (Table 1.5) (Korpi eta/., 1985, 1985a; Chang eta/., 1988, 
1991 ). The presence of RH in the plasma patients treated with HP was first reported by 
Forsman & Larsson (1978). However, the back conversion from RH to HP in human 
was not elucidated until1987. Back conversion of HP to RH in humans was detected in 
plasma from healthy volunteer subjects. Healthy volunteer subjects were 
administration of a single oral 5 mg dose of RH (Midha et a/., 1987). Two years later, 
these authors reported the interconversion between HP and RH in 14 of 15 normal 
volunteers who received a single 5 mg dose of HP and RH separately (Chakraborty et 
a/., 1989; Midha eta/., 1989). Further, Chang eta/. (1989a) also reported the reversible 
metabolism of HP and RH in schizophrenic patients (Table 1.6). The enzyme 
20 
responsible to produce RH from HP is characteristic of a ketone reductase that is 
present in human and guinea pig hepatic cytosol (lnaba & Kovac, 1989). The reductase 
activity was dependent on nicotinamide-adenine-dinucleotide-phosphate as a cofactor 
for both humans and guinea pigs. 
Several metabolic pathways involved in the metabolism of HP and RH 
are mediated by cytochrome P450 isoenzymes (CYP) (Usuki et a/., 1998). CYP3A4 
plays an important role and is responsible for the N-dealkylation of HP and RH (Pan et 
a/., 1997; Pan eta/., 1998a; Fang eta/., 1997), the back oxidation of HP to RH (Pan et 
a/., 1998a, Kudo & Odomi, 1998; Avent & Gillam, 1998; Fang eta/., 1997) and the 
formation of pyridinum metabolite (Avent & Gillam, 1998; Fang eta/., 1997; Eyles eta/., 
1996). There are however, in the literature, several suggestions based on in vivo and in 
vitro studies, that CYP2D6 (lnaba et a/., 1985; Tyndale et a/., 1991) could also be 
involved, but the metabolic pathways are not known. 
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Figure 1.3 Metabolism of HP (Forsman eta/., 1977). 
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1.3.4 DRUG INTERACTIONS 
A drug interaction usually refers to the modifications of the expected 
drug response due to exposure of the patients to other foods or drugs administered 
concomitantly. Drug interaction may include drug-drug interaction or drug-food 
interaction (Shargel & Yu, 1999). Food-drug interactions can produce negative effects 
in the safety and efficacy of drug therapy and in the nutritional status of the patients 
(Miguel et a/., 2005). Many nutrients substantially interfere with the absorption or 
metabolism of drugs in the body (Anderson, 1998; Kirk, 1995). For examples, grapes 
fruit juice increase the plasma level of many drugs such as lovastatin and simvastatin 
due to naringin that inhibit their metabolism (Kantola et a/., 1998). Fluoroquinolones 
binds with iron or calcium enriched foods and antacids if administered simultaneously. 
The resulting compounds excreted with little or no systemic absorption. Significant 
interaction of P-glycoproteins with cyclosporine and reduce the absorption of 
levofloxacin has been reported (Wallace eta/., 2003). 
Many drug-drug interactions are metabolism based and related to 
cytochrome P 450 (CYP) enzymes. The CYP enzyme system is a very large group of 
enzymes encoded by the P 450 superfamily. CYPs are membrane bound proteins with 
an approximate molecular weight of 50 kD and contain a heme moiety (Gunaratna, 
2000). Because of the diversity of the cytochrome family a nomenclature system based 
on sequence identity is developed. This nomenclature is comprised of family and sub-
family systems. Family includes CYPs and is designated by a number after CYP. Sub-
family is the GYPs within the family and is designated by a letter following the number. 
For example, CYP2D6 is a cytochrome P 450 enzyme. It belongs to family 2 and sub-
family D. The last number 6 refers to the sequence of discovery. There are about 30 
human cytochrome P 450 enzymes. Only 6 of them such as CYP1A2, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1 and CYP3A4 are mainly involved in drug metabolism. 
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Among these CYP3A4 is the most abundant and most clinically important isoenzymes 
in humans (Gunaratna, 2000). 
The enzymes involved in the metabolism of drug are altered by food and 
the co-administered drug. Enzyme induction is a drug or chemical-stimulated increase 
in enzyme activity usually due to an increase in the amount of enzyme present. 
Enzyme inhibition is substrate competition or due to direct inhibition of the drug 
metabolising enzymes, mainly CYP enzymes (Shargel & Yu, 1999). The CYP enzyme 
is important to the pharmacokinetics of psychotropic drugs. The result of inhibition is a 
higher plasma level of drug that can cause adverse effect. The result of induction is a 
lower plasma level of drug that can affect the therapeutic efficacy (Sharif, 2003). 
Concomitantly administered drugs may affect the pharmacokinetics of 
HP by influencing its metabolic clearance and its ability to bind to plasma proteins, and 
by causing alterations in hepatic blood flow. HP appears to be a moderately extracted 
drug. On a theoretical basis, alterations in protein binding of drugs with a low extraction 
ratio would have no influence on the pharmacokinetics of unbound drug at steady state. 
On the other hand, alterations of plasma protein binding of high extraction drugs would 
be predicted to cause a change in the clearance of unbound drug (Wilkinson & Shand, 
1975; Nies eta/., 1976; Blaschke, 1977). 
Table 1.7 shows pharmacokinetic interactions between HP and other 
drugs. Anticonvulsant drugs such as carbamazepine, phenytoin and phenobarbitone 
are classified as enzyme inducers. Clinically significant decrease in plasma 
concentration of HP was reported when coadministered with carbamazepine (Jann et 
a/., 1985; Kidron, et a/., 1985; Arana et a/., 1986). Another similar study showed 
decreased plasma concentration of HP when co-administered with phenytoin and 
phenobarbital (Linnoila et a/., 1980). There have been several reports on 
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